DGAP-Adhoc

Elanix Biotechnologies AG: CEO informs about planned cash capital increase with indirect subscription rights - Seite 2

factors and uncertainties such as changes in the business, economic and
competitive situation, exchange rate fluctuations, uncertainties regarding
litigation or investigation proceedings and the availability of financial
resources. Readers should therefore not place undue reliance on these
statements, particularly not in connection with any contract or investment
decision. The Elanix Biotechnologies AG disclaims any obligation to update
these forward-looking statements.

This communication does not constitute an offer or invitation to subscribe
for or purchase any securities of Elanix Biotechnologies AG. This
announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities to any person
in the United States of America (the "United States"), Australia, Canada or
Japan or in any jurisdiction to whom or in which such offer or solicitation
is unlawful. The securities referred to in this announcement will not be
and have not been registered under the U.S. Securities Act of 1933, as
amended (the "U.S. Securities Act") and may not be offered or sold in the
United States absent registration or an applicable exemption from
registration requirements under the U.S. Securities Act. Subject to certain
exceptions, the securities referred to in this announcement may not be
offered or sold in Australia, Canada or Japan, or to, or for the account or
benefit of, any national, resident or citizen of Australia, Canada or
Japan. The offer and sale of the securities referred to in this
announcement has not been and will not be registered under the U.S.
Securities Act or under the applicable securities laws of Australia, Canada
or Japan. There will be no public offer of the securities in the United
States.

This announcement also does not constitute a prospectus within the meaning
of the EU Directive 2003/71/EC of the European Parliament and of the
Council of 4 November 2003 as amended ("Prospectus Directive").

---------------------------------------------------------------------------

13-Jan-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Elanix Biotechnologies AG
Domstr. 22
14482 Potsdam
Germany
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard);
Regulated Unofficial Market in Berlin, Dusseldorf



End of Announcement DGAP News Service
---------------------------------------------------------------------------

536315 13-Jan-2017 CET/CEST